PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 10, 2026Expert Opinion on Biological Therapy0 citations

Itepekimab for chronic obstructive pulmonary disease therapy

View Full Paper
SASabina A AntoniuGrigore T. Popa University of Medicine and PharmacyTPTheodor PenisoaraGrigore T. Popa University of Medicine and PharmacyȘRȘtefan RașcuCarol Davila University of Medicine and Pharmacy

Key Points

  • The study aims to evaluate itepekimab as a feasible therapy for managing chronic obstructive pulmonary disease (COPD).
  • Review existing clinical data on itepekimab.
  • Assess dosing schedules for different disease phases.
  • Focus on home administration of therapy.
  • Itepekimab may provide effective management for COPD.
  • Dosing can be adjusted to every 2 weeks during exacerbations and every 4 weeks when stable.

Abstract

Based on existing clinical data, itepekimab may be a potential therapy for COPD that can be easily administered at home, with dosing tailored to the disease phase (every 2 weeks during exacerbation and every 4 weeks during stable state).

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Antoniu et al. (2026) studied this question.

synapsesocial.com/papers/69d895be6c1944d70ce06da3https://doi.org/10.1080/14712598.2026.2654773
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1AERIFY-1/2: two phase 3, randomised, controlled trials of itepekimab in former smokers with moderate-to-severe COPD2024 · 38 citations
  2. 2Role of thymic stromal lymphopoietin in allergy and beyond2022 · 281 citations
  3. 3Targeting cytokines to treat asthma and chronic obstructive pulmonary disease2018 · 429 citations
  4. 4IL-33 isoforms: their future as vaccine adjuvants?2015 · 28 citations
  5. 5The High Affinity Anti-IL-33 Antibody Itepekimab Potently Blocks IL-33 Induced Activation of the ST2/IL-1RAcP Signaling Complex and Inhibits Key Mediators of Airway Inflammation2024 · 1 citations